These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||||
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
| For the Transition Period from _____ to _____ | |||||
|
|
|
|||||||||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||
|
|
|
|||||||||||||
|
|
|
|
||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
|
|
|
|||||||||||||
| (Registrant's telephone number, including area code) | ||||||||||||||
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
|
|
|
|
||||||
| Large accelerated filer | ☐ |
|
x
|
Non-accelerated filer | ☐ | ||||||||||||
| Smaller reporting company |
|
Emerging growth company |
|
||||||||||||||
| PART I. FINANCIAL INFORMATION | |||||||||||
|
Item 1.
|
Financial Statements | ||||||||||
| Notes to Condensed Consolidated Financial Statements (unaudited) | |||||||||||
| Item 2. | |||||||||||
| Item 3. | |||||||||||
| Item 4. | |||||||||||
| PART II. OTHER INFORMATION | |||||||||||
| Item 1. | |||||||||||
|
Item 1A.
|
|||||||||||
| Item 2. | |||||||||||
| Item 3. | |||||||||||
| Item 4. | |||||||||||
| Item 5. | |||||||||||
| Item 6. | |||||||||||
| (Unaudited) | |||||||||||
| September 30, 2025 | December 31, 2024 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ |
|
$ |
|
|||||||
|
Accounts receivable, net of allowance for credit losses of $
|
|
|
|||||||||
| Advances and other receivables |
|
|
|||||||||
| Inventories |
|
|
|||||||||
| Prepaid expenses and other current assets |
|
|
|||||||||
| Current assets of discontinued operations |
|
|
|||||||||
| Total current assets |
|
|
|||||||||
| Property, plant and equipment, net |
|
|
|||||||||
| Right-of-use assets, operating leases, net |
|
|
|||||||||
| Intangible assets, net |
|
|
|||||||||
| Deferred charges, net |
|
|
|||||||||
| Other non-current assets, net |
|
|
|||||||||
| Long-term assets of discontinued operations |
|
|
|||||||||
| Total assets | $ |
|
$ |
|
|||||||
| Liabilities and Shareholders' Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ |
|
$ |
|
|||||||
| Accrued expenses and other current liabilities |
|
|
|||||||||
| Current portion of note payable |
|
|
|||||||||
| Current portion of operating lease liabilities |
|
|
|||||||||
| Current portion of finance lease liabilities |
|
|
|||||||||
| Current liabilities of discontinued operations |
|
|
|||||||||
| Total current liabilities |
|
|
|||||||||
| Long-term portion of operating lease liabilities |
|
|
|||||||||
| Long-term portion of finance lease liabilities |
|
|
|||||||||
| Deferred income taxes |
|
|
|||||||||
| Other long-term liabilities |
|
|
|||||||||
| Total non-current liabilities |
|
|
|||||||||
| Total liabilities | $ |
|
$ |
|
|||||||
| Commitments and contingencies – See Note 13 |
|
|
|||||||||
| Shareholders' equity: | |||||||||||
|
Common stock, par value $
|
$ |
|
$ |
|
|||||||
| Capital in excess of par value |
|
|
|||||||||
| Retained earnings |
|
|
|||||||||
|
|
|
||||||||||
|
Less: cost of common stock in treasury -
|
(
|
(
|
|||||||||
| Total shareholders' equity |
|
|
|||||||||
| Total liabilities and shareholders' equity | $ |
|
$ |
|
|||||||
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Cost of sales |
|
|
|
|
|||||||||||||||||||
| Gross profit |
|
|
|
|
|||||||||||||||||||
| Selling, general and administrative |
|
|
|
|
|||||||||||||||||||
| Acquisition costs and other |
|
|
|
|
|||||||||||||||||||
| Asset impairments |
|
|
|
|
|||||||||||||||||||
| Gain on lease modification |
|
(
|
(
|
(
|
|||||||||||||||||||
| Operating loss from continuing operations |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Other expense (income) | |||||||||||||||||||||||
| Interest expense (income), net |
(
|
|
(
|
|
|||||||||||||||||||
| Other, net |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Loss from continuing operations before income taxes |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Income tax expense (benefit) |
|
|
(
|
|
|||||||||||||||||||
| Loss from continuing operations |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Income (loss) from discontinued operations, net of tax |
(
|
|
|
|
|||||||||||||||||||
| Net income (loss) | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Net loss per common share from continuing operations: | |||||||||||||||||||||||
| Basic | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Diluted | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Net income (loss) per common share from discontinued operations: | |||||||||||||||||||||||
| Basic | $ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Diluted | $ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Net income (loss) per common share: | |||||||||||||||||||||||
| Basic | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Diluted | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Weighted average shares outstanding: | |||||||||||||||||||||||
| Basic |
|
|
|
|
|||||||||||||||||||
| Diluted |
|
|
|
|
|||||||||||||||||||
| Nine Months Ended September 30, | |||||||||||
| 2025 | 2024 | ||||||||||
| Operating activities | |||||||||||
| Net income (loss) | $ |
|
$ |
(
|
|||||||
| Income from discontinued operations, net of tax |
|
|
|||||||||
| Net loss from continuing operations |
(
|
(
|
|||||||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||||||||||
| Depreciation expense |
|
|
|||||||||
| Amortization expense |
|
|
|||||||||
| Amortization of debt issuance costs |
|
|
|||||||||
| Asset impairments |
|
|
|||||||||
| Deferred income taxes |
(
|
|
|||||||||
| (Reduction of) provision for losses on accounts receivable |
(
|
|
|||||||||
| Non-cash lease expense |
|
|
|||||||||
| Stock-based compensation expense |
|
|
|||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable and advances |
(
|
(
|
|||||||||
| Inventories |
(
|
|
|||||||||
| Other assets and liabilities |
(
|
(
|
|||||||||
| Accounts payable |
(
|
(
|
|||||||||
| Accrued expenses |
|
|
|||||||||
| Accrued income taxes |
(
|
|
|||||||||
| Net cash (used in) provided by operating activities - continuing operations |
(
|
|
|||||||||
| Net cash provided by operating activities - discontinued operations |
|
|
|||||||||
| Net cash (used in) provided by operating activities |
(
|
|
|||||||||
| Investing activities | |||||||||||
| Purchases of property, plant and equipment |
(
|
(
|
|||||||||
| Net cash used in investing activities - continuing operations |
(
|
(
|
|||||||||
| Net cash provided by investing activities - discontinued operations |
|
|
|||||||||
| Net cash provided by investing activities |
|
|
|||||||||
| Financing activities | |||||||||||
| Borrowings from credit facilities |
|
|
|||||||||
| Proceeds from note payable |
|
|
|||||||||
| Payments on credit facilities |
(
|
(
|
|||||||||
| Payments on note payable |
(
|
(
|
|||||||||
| Principal payments on finance lease obligations |
(
|
(
|
|||||||||
| Repurchase of common stock |
(
|
(
|
|||||||||
| Net cash used in financing activities - continuing operations |
(
|
(
|
|||||||||
| Net cash used in financing activities - discontinued operations |
(
|
(
|
|||||||||
| Net cash used in financing activities |
(
|
(
|
|||||||||
| Increase in cash and cash equivalents |
|
|
|||||||||
| Less: Cash and cash equivalents of discontinued operations |
|
|
|||||||||
| Cash and cash equivalents at beginning of period |
|
|
|||||||||
| Cash and cash equivalents at end of period | $ |
|
$ |
|
|||||||
| Supplemental Disclosure of Cash Flow Information | |||||||||||
| Cash paid for: | |||||||||||
| Interest | $ |
|
$ |
|
|||||||
| Noncash Investing Activities: | |||||||||||
| Capital expenditures, not yet paid | $ |
|
$ |
|
|||||||
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| Common Stock |
Capital in Excess of
Par Value |
Retained Earnings | Treasury Stock | Total | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Balance June 30, 2025 |
|
$ |
|
$ |
|
$ |
|
|
$ |
(
|
$ |
|
||||||||||||||||||||||||||||||||
| Net loss | — | — | — |
(
|
— |
(
|
||||||||||||||||||||||||||||||||||||||
|
Issuance of
|
— | — |
(
|
— |
(
|
|
|
|||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — |
|
— | — |
|
||||||||||||||||||||||||||||||||||||||
|
Repurchase of
|
— | — | — | — |
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 |
|
$ |
|
$ |
|
$ |
|
|
$ |
(
|
$ |
|
||||||||||||||||||||||||||||||||
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| Common Stock |
Capital in Excess of
Par Value |
Retained Earnings | Treasury Stock | Total | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2024 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||||||
| Net income | — | — | — |
|
— |
|
||||||||||||||||||||||||||||||||||||||
|
Issuance of
|
— | — |
(
|
— |
(
|
|
|
|||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — |
|
— | — |
|
||||||||||||||||||||||||||||||||||||||
|
Repurchase of
|
— | — | — | — |
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| Common Stock |
Capital in Excess of
Par Value |
Retained Earnings | Treasury Stock | Total | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Balance June 30, 2024 |
|
$ |
|
$ |
|
$ |
|
|
$ |
(
|
$ |
|
||||||||||||||||||||||||||||||||
| Net loss | — | — | — |
(
|
— |
(
|
||||||||||||||||||||||||||||||||||||||
|
Issuance of
|
— | — |
(
|
— |
(
|
|
|
|||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — |
|
— | — |
|
||||||||||||||||||||||||||||||||||||||
|
Repurchase of
|
— | — | — | — |
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2024 |
|
|
|
|
|
(
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Nine Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| Common Stock |
Capital in Excess of
Par Value |
Retained Earnings | Treasury Stock | Total | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2023 |
|
$ |
|
$ |
|
$ |
|
|
$ |
(
|
$ |
|
||||||||||||||||||||||||||||||||
| Net loss | — | — | — |
(
|
— |
(
|
||||||||||||||||||||||||||||||||||||||
|
Issuance of
|
— | — |
(
|
— |
(
|
|
|
|||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — |
|
— | — |
|
||||||||||||||||||||||||||||||||||||||
|
Repurchase
|
— | — | — | — |
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2024 |
|
|
|
|
|
(
|
$ |
|
||||||||||||||||||||||||||||||||||||
| (in thousands) | September 30, 2025 | December 31, 2024 | |||||||||
| Carrying amounts of assets included as part of discontinued operations: | |||||||||||
| Cash and cash equivalents | $ |
|
$ |
|
|||||||
| Accounts receivable, net |
|
|
|||||||||
| Inventories |
|
|
|||||||||
| Prepaid expenses and other current assets |
|
|
|||||||||
| Current assets classified as discontinued operations |
|
|
|||||||||
| Property, plant and equipment, net |
|
|
|||||||||
| Right-of-use assets, operating leases, net |
|
|
|||||||||
| Intangible assets, net |
|
|
|||||||||
| Other non-current assets, net |
|
|
|||||||||
| Long-term assets classified as discontinued operations |
|
|
|||||||||
| Total assets classified as discontinued operations | $ |
|
$ |
|
|||||||
| Carrying amounts of current liabilities included as part of discontinued operations: | |||||||||||
| Accounts payable |
|
|
|||||||||
| Deferred revenue |
|
|
|||||||||
| Accrued expenses and other current liabilities |
|
|
|||||||||
| Current portion of operating lease liabilities |
|
|
|||||||||
| Current portion of finance lease liabilities |
|
|
|||||||||
| Current liabilities classified as discontinued operations |
|
|
|||||||||
| Total liabilities classified as discontinued operations | $ |
|
$ |
|
|||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Cost of sales |
|
|
|
|
|||||||||||||||||||
| Gross profit |
|
|
|
|
|||||||||||||||||||
| Selling, general and administrative expense |
|
|
|
|
|||||||||||||||||||
| Loss (gain) on sale of assets |
|
(
|
(
|
(
|
|||||||||||||||||||
| Acquisition costs and other |
|
|
|
|
|||||||||||||||||||
| Asset impairments |
|
|
|
|
|||||||||||||||||||
| Income (loss) on discontinued operations before income taxes |
(
|
|
|
|
|||||||||||||||||||
| Income tax expense (benefit) |
|
|
(
|
|
|||||||||||||||||||
| Net income (loss) from discontinued operations | $ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||||
| Custom Manufacturing | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Product Innovation & Sales |
|
|
|
|
|||||||||||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
|||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||
| Point-in-time | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||
| Over-time | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||
| (in thousands) | September 30, 2025 | December 31, 2024 | |||||||||
| Raw materials | $ |
|
$ |
|
|||||||
| Finished goods |
|
|
|||||||||
|
|
|
||||||||||
| Less: inventory reserves |
(
|
(
|
|||||||||
| Inventories | $ |
|
$ |
|
|||||||
| (in thousands) | September 30, 2025 | December 31, 2024 | |||||||||
| Land | $ |
|
$ |
|
|||||||
| Leasehold improvements |
|
|
|||||||||
| Buildings |
|
|
|||||||||
| Machinery, fixtures and equipment |
|
|
|||||||||
| Construction-in-progress |
|
|
|||||||||
|
|
|
||||||||||
| Less: accumulated depreciation and amortization |
(
|
(
|
|||||||||
| Property, plant and equipment, net | $ |
|
$ |
|
|||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||||
| Cost of sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Selling, general and administrative |
|
|
|
|
|||||||||||||||||||||||||||||||
| Total depreciation | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| September 30, 2025 | December 31, 2024 | ||||||||||||||||
| (in thousands) | Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | |||||||||||||
| Definite-lived intangible assets: | |||||||||||||||||
| Customer related | $ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||
| Trademarks and trade names |
|
(
|
|
(
|
|||||||||||||
| Other |
|
(
|
|
(
|
|||||||||||||
| Total definite-lived intangible assets | $ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||
| (in thousands) | ||||||||||||||
| Remainder of 2025 | $ |
|
||||||||||||
| 2026 |
|
|||||||||||||
| 2027 |
|
|||||||||||||
| 2028 |
|
|||||||||||||
| 2029 |
|
|||||||||||||
| 2030 |
|
|||||||||||||
| Thereafter |
|
|||||||||||||
| (in thousands) | September 30, 2025 | December 31, 2024 | |||||||||
| Deferred charges, gross | $ |
|
$ |
|
|||||||
| Accumulated amortization of deferred charges |
(
|
(
|
|||||||||
| Deferred charges, net | $ |
|
$ |
|
|||||||
| Classification | Financial Statement Line Item | September 30, 2025 | December 31, 2024 | |||||||||||||||||
| Long-term Assets | Right-of-use assets, operating leases | $ |
|
$ |
|
|||||||||||||||
| Long-term Assets | Property, plant and equipment |
|
|
|||||||||||||||||
| Current liabilities | Current portion of lease liabilities, operating leases |
|
|
|||||||||||||||||
| Current liabilities | Current portion of lease liabilities, finance leases |
|
|
|||||||||||||||||
| Non-current liabilities | Non-current portion of lease liabilities, operating leases |
|
|
|||||||||||||||||
| Non-current liabilities | Non-current portion of lease liabilities, finance leases |
|
|
|||||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
|
Operating lease cost
1
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Finance lease cost: | |||||||||||||||||||||||
| Amortization of right-of-use assets |
|
|
|
|
|||||||||||||||||||
| Interest on finance lease liabilities |
|
|
|
|
|||||||||||||||||||
| Sublease income |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Total lease cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| (in thousands) | Sublease Receipts | ||||
| Remainder of 2025 | $ |
|
|||
| 2026 |
|
||||
| 2027 |
|
||||
| 2028 |
|
||||
| 2029 |
|
||||
| Thereafter |
|
||||
| Total sublease receipts | $ |
|
|||
| (in thousands) | Operating | Finance | |||||||||
| Remainder of 2025 | $ |
|
$ |
|
|||||||
| 2026 |
|
|
|||||||||
| 2027 |
|
|
|||||||||
| 2028 |
|
|
|||||||||
| 2029 |
|
|
|||||||||
| Thereafter |
|
|
|||||||||
| Total undiscounted minimum future lease payments |
|
|
|||||||||
| Imputed interest |
(
|
(
|
|||||||||
| Present value of lease liabilities | $ |
|
$ |
|
|||||||
| Weighted-average remaining lease term | September 30, 2025 | December 31, 2024 | |||||||||
| Operating leases |
|
|
|||||||||
| Finance leases |
|
|
|||||||||
| Weighted-average discount rate | |||||||||||
| Operating leases |
|
% |
|
% | |||||||
| Finance leases |
|
% |
|
% | |||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
|||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||
|
Number of shares repurchased
1
|
|
|
|
|
||||||||||||||||
| Average price per share | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||
|
Total cost of shares repurchased
2
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||
| (in thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Numerator: | |||||||||||||||||||||||
| Net loss from continuing operations | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Net income (loss) from discontinued operations | $ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Net income (loss) | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Denominator: | |||||||||||||||||||||||
| Weighted-average common shares outstanding |
|
|
|
|
|||||||||||||||||||
| Effect of dilutive securities: | |||||||||||||||||||||||
| Employee stock options and stock grants |
|
|
|
|
|||||||||||||||||||
| Weighted-average common shares, as adjusted |
|
|
|
|
|||||||||||||||||||
| Net loss per share from continuing operations: | |||||||||||||||||||||||
| Basic | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Diluted | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Net income (loss) per share from discontinued operations: | |||||||||||||||||||||||
| Basic | $ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Diluted | $ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Net income (loss) per share: | |||||||||||||||||||||||
| Basic | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Diluted | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Income tax expense (benefit) | $ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||
| Effective income tax rate |
(
|
% |
(
|
% |
|
% |
(
|
% | |||||||||||||||
|
Three Months Ended
September 30, 2025 |
Nine Months Ended
September 30, 2025 |
|||||||||||||||||||||||||||||||||||||
| (in thousands) | Specialty Chemicals |
Corporate & Other
1
|
Total Continuing Operations | Specialty Chemicals |
Corporate & Other
1
|
Total Continuing Operations | ||||||||||||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Cost of goods sold - material |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
Cost of goods sold - other
2
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Gross profit |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
Selling, general and administrative expense
3
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Acquisition costs and other |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Asset impairments |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Gain on lease modification |
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Interest expense (income), net |
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Income taxes |
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Other expense (income) |
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Net income (loss) | $ |
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
|
Three Months Ended
September 30, 2024 |
Nine Months Ended
September 30, 2024 |
|||||||||||||||||||||||||||||||||||||
| (in thousands) | Specialty Chemicals |
Corporate & Other
1
|
Total Continuing Operations | Specialty Chemicals |
Corporate & Other
1
|
Total Continuing Operations | ||||||||||||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Cost of goods sold - material |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
Cost of goods sold - other
2
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Gross profit |
|
(
|
|
|
(
|
|
||||||||||||||||||||||||||||||||
|
Selling, general and administrative expense
3
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Acquisition costs and other |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Gain on lease modification |
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Interest expense, net |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Income taxes |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other expense (income) |
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Net income (loss) | $ |
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
| As of | |||||||||||
| (in thousands) | September 30, 2025 | December 31, 2024 | |||||||||
| Identifiable assets | |||||||||||
| Specialty Chemicals | $ |
|
$ |
|
|||||||
| Corporate and other |
|
|
|||||||||
| $ |
|
$ |
|
||||||||
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||||||||||||
| ($ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Consolidated | ||||||||||||||||||||||||||
| Net loss from continuing operations | $ | (125) | $ | (7,801) | $ | (4,577) | $ | (12,731) | ||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||
| Interest expense (income), net | (447) | 124 | (347) | 323 | ||||||||||||||||||||||
| Income taxes | 58 | 5,807 | (32) | 4,413 | ||||||||||||||||||||||
| Depreciation | 854 | 962 | 2,725 | 2,923 | ||||||||||||||||||||||
| Amortization | 153 | 174 | 458 | 522 | ||||||||||||||||||||||
| EBITDA | 493 | (734) | (1,773) | (4,550) | ||||||||||||||||||||||
| Acquisition costs and other | 398 | 2 | 665 | 54 | ||||||||||||||||||||||
| Asset impairments | — | — | 1,622 | — | ||||||||||||||||||||||
| Gain on lease modification | — | (67) | (544) | (67) | ||||||||||||||||||||||
| Stock-based compensation | 197 | 55 | 318 | 148 | ||||||||||||||||||||||
| Non-cash lease expense | 86 | 35 | 85 | 96 | ||||||||||||||||||||||
| Retention expense | — | — | — | 3 | ||||||||||||||||||||||
| Restructuring and severance cost | 202 | — | 202 | 177 | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 1,376 | $ | (709) | $ | 575 | $ | (4,139) | ||||||||||||||||||
| % of sales | 7.0 | % | (3.4) | % | 1.0 | % | (6.6) | % | ||||||||||||||||||
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||||||||||||
| ($ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Specialty Chemicals | ||||||||||||||||||||||||||
| Net income (loss) | $ | 2,138 | $ | 367 | $ | 4,375 | $ | (681) | ||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||
| Interest expense, net | 7 | 19 | 39 | 57 | ||||||||||||||||||||||
| Depreciation | 830 | 945 | 2,671 | 2,863 | ||||||||||||||||||||||
| Amortization | 153 | 174 | 458 | 522 | ||||||||||||||||||||||
| EBITDA | 3,128 | 1,505 | 7,543 | 2,761 | ||||||||||||||||||||||
| Acquisition costs and other | — | — | 92 | — | ||||||||||||||||||||||
| Stock-based compensation | 4 | — | 4 | 7 | ||||||||||||||||||||||
| Non-cash lease expense | 26 | 19 | 30 | 57 | ||||||||||||||||||||||
| Restructuring and severance costs | — | — | — | 109 | ||||||||||||||||||||||
| Specialty Chemicals Adjusted EBITDA | $ | 3,158 | $ | 1,524 | $ | 7,669 | $ | 2,934 | ||||||||||||||||||
| % of segment sales | 16.0 | % | 7.3 | % | 13.7 | % | 4.7 | % | ||||||||||||||||||
| Nine Months Ended September 30, | |||||||||||
| (in thousands) | 2025 | 2024 | |||||||||
| Total cash (used in) provided by: | |||||||||||
| Operating activities | $ | (7,568) | $ | 924 | |||||||
| Investing activities | (1,082) | (737) | |||||||||
| Financing activities | (8,705) | (676) | |||||||||
| Net decrease in cash and cash equivalents | $ | (17,355) | $ | (489) | |||||||
| Three Months Ended September 30, |
Nine Months Ended
September 30, |
|||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||
| Number of shares repurchased | 64,782 | 42,623 | 725,775 | 74,186 | ||||||||||||||||
| Average price per share | $ | 12.85 | $ | 9.79 | $ | 12.23 | $ | 9.92 | ||||||||||||
| Total cost of shares repurchased | $ | 834,520 | $ | 418,563 | $ | 8,897,903 | $ | 738,361 | ||||||||||||
| September 30, 2025 | December 31, 2024 | |||||||||||||||||||
| Current ratio | 6.4 | 2.8 | ||||||||||||||||||
| Return on average equity | (7.2)% | (34.0)% | ||||||||||||||||||
| Period | Total Number of Shares Purchased | Average Price Paid per Share |
Total Number of Shares Purchased as Part of Publicly Announced Programs
1
|
Number of Shares that May Yet Be Purchased under the Program | |||||||||||||||||||
| July 1, 2025 - July 31, 2025 | 56,389 | $ | 12.86 | 56,389 | 283,363 | ||||||||||||||||||
| August 1, 2025 - August 31, 2025 | 8,393 | 12.77 | 8,393 | 274,970 | |||||||||||||||||||
| September 1, 2025 - September 30, 2025 | — | — | — | 274,970 | |||||||||||||||||||
| As of September 30, 2025 | 64,782 | $ | 12.85 | 64,782 | 274,970 | ||||||||||||||||||
| Exhibit No. |
Description
|
|||||||
| 101.INS* | XBRL Instance Document | |||||||
| 101.SCH* | XBRL Taxonomy Extension Schema | |||||||
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase | |||||||
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase | |||||||
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase | |||||||
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101*) | |||||||
| * | In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed "furnished" and not "filed." | |||||||
| ASCENT INDUSTRIES CO. | |||||||||||
| (Registrant) | |||||||||||
|
Date:
|
November 4, 2025 | By: | /s/ J. Bryan Kitchen | ||||||||
| J. Bryan Kitchen | |||||||||||
| President and Chief Executive Officer | |||||||||||
| (principal executive officer) | |||||||||||
|
Date:
|
November 4, 2025 | By: | /s/ Ryan Kavalauskas | ||||||||
| Ryan Kavalauskas | |||||||||||
| Chief Financial Officer | |||||||||||
| (principal accounting officer) | |||||||||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|